Biomarkers help identify people on the path to Alzheimer’s, but so far have not proved useful as surrogate outcome measures for clinical improvement in trials. Because cognitive loss correlates with damage to synapses, synaptic markers might do a better job of tracking clinical outcomes. However, these proteins occur in very low levels in cerebrospinal fluid (CSF), making them difficult to measure. In two recent papers, researchers at the University of Gothenburg, Sweden, described methods for detecting SNAP-25 and neurogranin in the CSF of individual patients. In three small, independent cohorts, levels of these synapse proteins were higher in people with Alzheimer’s dementia than in controls, the scientists reported. Moreover, elevated neurogranin in people who were cognitively impaired predicted progression to dementia, and correlated with a swifter rate of cognitive decline. The results hint that these markers could be useful as both early diagnostics and outcome measures, although this remains to be confirmed in larger studies and clinical trials, noted Kaj Blennow, a senior author on both studies.
Other researchers praised the methodology of the studies and noted that the markers offer promise. “The technical characterization and validation of the methods used is quite exemplary,” Marc Gleichmann at EMD Serono, Billerica, Massachusetts, a division of Merck, wrote to Alzforum (see full comment below). “Both CSF-SNAP25 and CSF-Ng are welcome additions to the existing CSF biomarkers, and further use and characterization is warranted.”
In previous investigations, the Gothenburg group had to pool CSF samples to detect synaptic proteins (see, e.g., Davidsson et al., 1999; Thorsell et al., 2010). To improve sensitivity, the researchers used monoclonal antibodies to purify each synaptic target protein from spinal fluid, then quantified each with mass spectrometry. This refinement allowed the detection of the proteins in CSF samples from individual patients, according to the new papers.
For synaptosomal-associated protein 25 (SNAP-25), first author Ann Brinkmalm compared CSF levels in three separate cohorts that together comprised 36 AD patients and 32 age-matched controls. In every group, patients had significantly higher SNAP-25 on average than controls. One cohort also included seven people with prodromal AD, who displayed intermediate levels of SNAP-25. SNAP-25 levels correlated with CSF total tau and phosphorylated tau, but not with Aβ42, suggesting that the marker tracks neurodegeneration. Among Alzheimer’s patients, SNAP-25 also correlated with the degree of cognitive impairment, as measured by scores on the MMSE.
The results parallel those for neurogranin. Joint first authors Hlin Kvartsberg and Flora Duits compared CSF levels of this postsynaptic marker in three separate cohorts totaling 100 AD patients and 80 controls, and an additional 40 people diagnosed with mild cognitive impairment (MCI). Patients had more neurogranin in the CSF than did controls in all studies. Among the MCI group, those judged to have prodromal AD had neurogranin levels that resembled those in patients, while those with other forms of MCI looked like controls. In addition, MCI patients with high neurogranin levels had 13 times higher odds of progressing to dementia than those without. Higher levels of neurogranin also predicted a steeper rate of decline on the MMSE in the prodromal AD patients. As with SNAP-25, neurogranin levels correlated with CSF total tau and phosphorylated tau, but not with Aβ42.
The presence of synaptic proteins in CSF likely reflects degeneration of synapses, Blennow told Alzforum. Tau, on the other hand, may measure breakdown of axons and cell bodies. “We show that they correlate, but we don’t believe they tell you the same thing,” Blennow noted. The exact staging of these markers will require longitudinal studies, he added. Currently, Blennow and colleagues are measuring neurogranin levels in CSF samples from the Alzheimer’s Disease Neuroimaging Initiative to see if the findings repeat. They are also setting up collaborations to test the synaptic markers’ usefulness as outcome measures in clinical trials.
Commentators suggested other experiments, as well. “It will be interesting to correlate the SNAP-25 and neurogranin makers with non-CSF putative markers of neuronal and synaptic injury, such as hippocampal atrophy or even tau PET imaging. It will also be important to learn whether these synaptic markers identify cognitively normal individuals with preclinical AD,” John Morris at Washington University in St. Louis wrote to Alzforum.
Will the methods for measuring these synaptic markers be practical for widespread use? Most larger Alzheimer’s centers have mass spec equipment and could perform these protocols, Blennow said. In addition, the researchers measured neurogranin using an ELISA assay, and obtained comparable results to the mass spec approach. ELISAs are simpler and more convenient for smaller laboratories, suggesting this biomarker could be widely adopted.—Madolyn Bowman Rogers
- Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 1999 Mar;20(3):431-7. PubMed.
- Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 2010 Nov 29;1362:13-22. Epub 2010 Sep 25 PubMed.
- Research Brief: VILIP-1 a Potential CSF Marker for AD?
- Brain Proteins in Flux a Decade Before Familial AD Begins
- Aβ*56 Found in Human CSF, Correlates With Tau?
- EEG: Coming in From the Margins of Alzheimer’s Research?
- CTAD: EEG Gains Luster as More Trials Incorporate Biomarkers
- Protein Marker Distinguishes Prion Disease from Rapid Alzheimer’s
- Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2015 Oct;11(10):1180-90. Epub 2014 Dec 19 PubMed.
- Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L, Hansson O, Wallin A, Zetterberg H, Blennow K, Öhrfelt A. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener. 2014 Nov 23;9:53. PubMed.